Loading
A phase 2 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Genentech, Inc., active and no longer recruiting.
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis is a phase 2 interventional study registered as NCT06096779 by Genentech, Inc., with 30 participants enrolled, started 2024-07-15 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/